Novartis (NVS) Reports In-Line Q3 EPS of $1.21; Guides FY15 Sales Growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% as AI buildout costs, Fed rate outlook weigh
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Novartis (NVS) Receives FDA Approval for Afinitor Disperz Labeling Amendment
January 26, 2015 2:17 PM ESTNovartis (NYSE: NVS) received FDA approval of a labeling revision for Afinitor Disperz (everolimus).
In a letter to Novartis (which is embedded below), the FDA stated: This Prior Approval supplemental new drug application revises the ADVERSE REACTIONS, Clinical Study Experience in Renal Angiomyolipoma with... More
